Equillium, Inc. (EQ)
NASDAQ: EQ · IEX Real-Time Price · USD
1.400
0.00 (0.00%)
At close: May 24, 2024, 4:00 PM
1.420
+0.020 (1.43%)
After-hours: May 24, 2024, 6:34 PM EDT

Company Description

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need.

The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.

It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications.

In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area.

The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017.

Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Equillium, Inc.
Equillium logo
Country United States
Founded 2017
IPO Date Oct 11, 2018
Industry Biotechnology
Sector Healthcare
Employees 44
CEO Bruce D. Steel C.F.A.

Contact Details

Address:
2223 Avenida De La Playa, Suite 105
La Jolla, California 92037
United States
Phone (858) 412-5302
Website equilliumbio.com

Stock Details

Ticker Symbol EQ
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001746466
CUSIP Number 29446K106
ISIN Number US29446K1060
Employer ID 82-1554746
SIC Code 2834

Key Executives

Name Position
Daniel Mark Bradbury Executive Chairman
Bruce D. Steel C.F.A. Co-Founder, President, Chief Executive Officer and Director
Christine Zedelmayer M.B.A., P.M.P. Senior Vice President and Chief Operating Officer
Dr. Stephen Connelly Ph.D. Chief Scientific Officer and Director
Jason A. Keyes Chief Financial Officer
Penny Tom Senior Vice President of Finance and Principal Accounting Officer
Michael Moore Vice President of Investor Relations and Corporate Communications
Dr. Matthew Ritter Ph.D. Senior Vice President of Corporate Development
Joel M. Rothman Chief Development Officer
Dr. Maple Fung M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
May 23, 2024 8-K Current Report
May 9, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report
Apr 11, 2024 ARS Filing
Apr 11, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 11, 2024 DEF 14A Other definitive proxy statements
Apr 1, 2024 PRE 14A Other preliminary proxy statements
Apr 1, 2024 8-K Current Report
Mar 25, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 25, 2024 10-K Annual Report